The race to develop effective cancer vaccines has entered a new phase, with late-stage trials from companies like Moderna ...

A large-scale real-world study in the USA has reinforced the effectiveness of Beyfortus (nirsevimab-alip), the respiratory ...

UK-based Rosemont Pharmaceuticals has appointed a new chair with a wealth of experience in the US pharma market.

UK government-backed Cell and Gene Therapy Catapult (CGT Catapult), a tech and innovation organization specializing in the ...

Swiss contract development and manufacturing group Lonza (SWX: LONN) posted a 19% rise in revenue at constant currencies to 3 ...

US healthcare giant Johnson & Johnson has announced that the European Commission (EC) has approved a new indication and an indication extension for Darzalex (daratumumab) and Imbruvica (ibrutinib), ...

Russian nano giant Rusnano is cutting its pharmaceutical business by beginning a search for buyers for its major ...

Privately-held Spanish CNS specialist Minoryx Therapeutics and Germany’s Neuraxpharm Group today announce that the marketing authorization application (MAA) for Minoryx’ lead candidate Nezglyal ...

Dispatch Bio has announced its official launch, with the stated ambition of engineering a universal treatment across solid tumors, which represent approximately 90% of cancers worldwide.

Switzerland-based Pharvaris yesterday announced the pricing of an underwritten offering of: 8,250,000 of its ordinary shares at a price of $20.00 per share and to one investor, pre-funded warrants to ...

Once dominated by Western markets, China and India are now emerging as leaders in small molecule development. Indeed, they ...

The European Commission has approved Swiss pharma giant Roche’s Itovebi (inavolisib), in combination with palbociclib ...